• WHO defends data after concluding Gilead's remdesivir flopped COVID trial
    ZURICH/GENEVA, October 16 (Reuters): A World Health Organization (WHO) trial that concluded Gilead Sciences Inc. remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated it said on Friday, as the U.S. company criticized its methodology. "It's a reliable result, don't let anybody tell you otherwise, because they'll try to," Richard Peto, an independent statistician hired by the WHO to evaluate its Solidarity trial, told repo
  • European countries face shortages of COVID-19 drug remdesivir
    AMSTERDAM/WARSAW/BRUSSELS, October 6 (Reuters): European countries are facing shortages of COVID-19 drug remdesivir because limited supplies are running out, officials said, with cases surging and the United States having bought up most of drugmaker Gilead's output. In July, the 27 European Union countries and Britain, with a combined population of 500 million, secured doses to treat about 30,000 patients. The United States signed a deal for more than 500,000 courses of tre
  • Cadila launches India's cheapest Remdesivir drug
    New Delhi, August 13 (PTI): Drug firm Zydus Cadila on Thursday said it has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market. Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing. The company said the drug will be made available across India through the group's strong distribution chain reaching out to government
  • Gilead's remdesivir set to become Europe's first COVID-19 therapy
    Reuters   Doctors in Europe will soon be able to treat COVID-19 patients with Gilead's antiviral drug, remdesivir, after the healthcare regulator's endorsement put it on track to become the first therapy for the disease on the continent.   The European Medicines Agency (EMA) said on Thursday its human medicines committee (CHMP) recommended conditionally approving the drug for adults and adolescents from 12 years of age who are also suffering from pneumonia
  • Gilead's remdesivir shows promise in COVID-19 study on monkeys
    Reuters Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaque monkeys infected with the new coronavirus, a study published in medical journal Nature showed on Tuesday.   Remdesivir is the first drug to show improvement in COVID-19 in human trials, and its progress in clinical studies is being closely watched as nations look for a treatment for the disease, which has infected more than 7 million people and killed over 400,000.  
  • India approves emergency use of remdesivir to treat COVID-19 patients
    BENGALURU, June 2 (Reuters): India's government said on Tuesday it has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use in treating COVID-19 patients.   Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials. It was granted emergency use authorization by the U.S. Food and Drug Administration last month and has received approval by Japanese health regulators.   "(Remdesivir) approv